Hutchinson-Gilford progeria syndrome

"Oscars ® of Science" Awards Six $3 Million Prizes GLP-1 Diabetes and Obesity Discovery | Multiple Sclerosis Causes and Treatments | DNA Editing Exploration of Nature at Shortest Distances Proof of Geometric Langlands Conjecture Special Prize Awarded to Giant of Theoretical Physics Breakthrough Prize in Life Sciences Awarded to Daniel J. Drucker, Joel Habener, Jens Juul Holst, Lotte Bjerre Knudsen and Svetlana Mojsov; Alberto Ascherio and Stephen L. Hauser; and David R. Liu Breakthrough Prize in Fundamental Physics Awarded to More than 13,000 Researchers from ATLAS, CMS , ALICE and LHCb Experiments at CERN Breakthrough Prize in Mathematics Awarded to Dennis Gaitsgory Special Breakthrough Prize in Fundamental Physics Awarded to Gerardus 't Hooft Six New Horizons Prizes Awarded for Early-Career Achievements in Physics and Mathematics Three Maryam Mirzakhani New Frontiers Prizes Awarded to Women Mathematicians for Early-Career Work Laureates Announced and Honored at Annual Breakthrough Prize Ceremony in Los Angeles LOS ANGELES, April 5, 2025 /PRNewswire/ -- The Breakthrough Prize Foundation today announced the winners of the 2025 Breakthrough Prizes, honoring scientists driving remarkable discoveries in gene editing, human diseases, the fundamental particles of the Universe and its underlying mathematical principles. The Breakthrough Prize – popularly known as the "Oscars ® of Science" – was created to celebrate the wonders of our scientific age by founding sponsors Sergey Brin, Priscilla Chan and Mark Zuckerberg, Julia and Yuri Milner, and Anne Wojcicki. Six Breakthrough Prizes of $3 million each were awarded in Life Sciences, Fundamental Physics, and Mathematics. In addition, the foundation announced eight early-career physicists and mathematicians are sharing six $100,000 New Horizons Prizes. Three women mathematicians recently completing PhDs are each receiving a $50,000 Maryam Mirzakhani New Frontiers Prize. This year's prize money totals $18.75 million, bringing the amount conferred over the 14 years of the Breakthrough Prize to more than $326 million. "This year's Breakthrough Prize laureates have made amazing strides – including treatments for major diseases affecting millions of people worldwide – showing once again the transformative power of curiosity-driven basic science." – Priscilla Chan and Mark Zuckerberg "The questions these laureates are asking are among the deepest questions there are – about the workings of life, the nature of the Universe and the abstract landscapes of mathematics. It's inspiring to see scientists seeking and finding answers to these questions." – Yuri Milner "The breakthroughs being recognized this year are extraordinary – including, in my own field, amazing gene-editing technologies that are already having a big impact. I'm excited to learn more about the scientists' ideas across all the fields." – Anne Wojcicki Life Sciences Daniel J. Drucker, Joel Habener, Jens Juul Holst, Lotte Bjerre Knudsen and Svetlana Mojsov share the Breakthrough Prize in Life Sciences. These five scientists' complementary contributions – from basic hormone discovery through physiological understanding to pharmaceutical development – have led to highly effective drugs for diabetes and obesity, ushering in a new era of GLP-1 medicines for cardiometabolic disorders. Between them their breakthroughs include: the discovery of the gene encoding the GLP-1 hormone; the synthesis, isolation and characterization of the hormone's biologically active forms; the demonstration that it is produced in the gut and stimulates insulin production; elucidation of its broader physiological roles, including control of appetite and energy homeostasis; the development of a more stable version of the hormone that continues to act in the body for days rather than hours; and its translation into a new class of drugs that is transforming the treatment of metabolic diseases affecting hundreds of millions of people worldwide. Stephen L. Hauser and Alberto Ascherio share the Breakthrough Prize in Life Sciences. The two researchers have transformed the understanding and treatment of multiple sclerosis (MS), a debilitating neurodegenerative disease in which the immune system attacks the insulating protein around nerve fibers. Among other contributions, Hauser overturned the scientific consensus on the mechanism of MS, identifying the immune system's B cells as the primary driver of damage to nerve cells. He was also instrumental in the development and testing of B cell-depleting therapies, which have revolutionized modern treatment of the disease. Meanwhile, through painstaking long-term epidemiological analysis, Ascherio discovered the necessary condition for getting MS: infection with the Epstein-Barr virus (EBV). The majority of the population carries this pathogen, normally without severe effects, but Ascherio showed that contracting it raises the risk of developing MS by a factor of 32. This work opens the possibility of treating MS with antiviral drugs, and for the development of a vaccine for EBV that could effectively prevent MS altogether. David R. Liu is awarded the Breakthrough Prize in Life Sciences for developing two powerful, widely used gene-editing technologies. These technologies are engineered molecular machines that correct mutations in our DNA that cause genetic diseases in patients. Importantly, they do not require cutting the DNA double-helix, and thus lead to fewer unwanted outcomes. In 2016 Liu's lab developed base editing, which corrects the single-letter "misspellings" that constitute about 30 percent of mutations known to cause genetic diseases. Then in 2019 his lab invented prime editing, which replaces whole stretches of defective DNA with a corrected version, and in principle could be used to repair nearly all disease-causing mutations. These technologies have already been distributed more than 20,000 times to labs around the world, resulting in thousands of published advances in research, agriculture, and biomedicine. In animals, base editing and prime editing have successfully corrected mutations to rescue blood diseases such as sickle-cell disease and beta-thalassemia, neurological disorders such as ALS and spinal muscular atrophy (SMA), muscle diseases such as muscular dystrophy and cardiomyopathies, genetic forms of blindness, genetic forms of hearing loss, several metabolic disorders, and progeria, a premature aging disease. At least 15 base editing and prime editing clinical trials have begun in five countries, with beneficial and, in some cases, life-saving results already confirmed in patients for the treatment of T-cell leukemia, sickle-cell disease, beta-thalassemia, and high cholesterol. Fundamental Physics The Breakthrough Prize in Fundamental Physics is awarded to thousands of researchers from more than 70 countries representing four experimental collaborations at CERN's Large Hadron Collider (LHC) – ATLAS, CMS, ALICE and LHCb. The $3 million prize is allocated to ATLAS ($1 million); CMS ($1 million), ALICE ($500,000) and LHCb ($500,000), in recognition of 13,508 co-authors of publications based on LHC Run-2 data released between 2015 and July 15, 2024. [ATLAS – 5,345 researchers; CMS – 4,550; ALICE – 1,869; LHCb – 1,744]. In consultation with the leaders of the experiments, the Breakthrough Prize Foundation will donate 100 percent of the prize funds to the CERN & Society Foundation. The prize money will be used by the collaborations to offer grants for doctoral students from member institutes to spend research time at CERN, giving the students experience working at the forefront of science and new expertise to bring back to their home countries and regions. The four experiments are recognized for testing the modern theory of particle physics – the Standard Model – and other theories describing physics that might lie beyond it to high precision. This includes precisely measuring properties of the Higgs boson and elucidating the mechanism by which the Higgs field gives mass to elementary particles; probing extremely rare particle interactions, and exotic states of matter that existed in the first moments of the Universe; discovering more than 72 new hadrons and measuring subtle differences between matter and antimatter particles; and setting strong bounds on possibilities for new physics beyond the Standard Model, including dark matter, supersymmetry and hidden extra dimensions. ATLAS and CMS are general-purpose experiments, which pursue the full program of exploration offered by the LHC's high-energy and high-intensity proton and ion beams. They synchronously announced the discovery of the Higgs boson in 2012 and continue to investigate its properties. ALICE studies the quark-gluon plasma, a state of extremely hot and dense matter that existed in the first microseconds after the Big Bang. And LHCb explores minute differences between matter and antimatter, violation of fundamental symmetries, and the complex spectra of composite particles ("hadrons") made of heavy and light quarks. By performing these extraordinarily precise and delicate tests, the LHC experiments have pushed the boundaries of fundamental physics to unprecedented limits. Mathematics Dennis Gaitsgory wins the Breakthrough Prize in Mathematics for his central role in the proof of the geometric Langlands conjecture. The Langlands program is a broad research program spanning several fields of mathematics. It grew out of a series of conjectures proposing precise connections between seemingly disparate mathematical concepts. Such connections are powerful tools; for example, the proof of Fermat's Last Theorem reduces to a particular instance of the Langlands conjecture. These Langlands program equivalences can be thought of as generalizations of the Fourier transform, a tool that relates waves to frequency spectrums and has widespread uses from seismology to sound engineering. In the case of the geometric Langlands conjecture, the proposed one-to-one correspondence is between two very different sets of objects, analogous to these spectrums and waves: on the spectrum side are abstract algebraic objects called representations of the fundamental group, which capture information about the kinds of loop that can wrap around certain complex surfaces; on the "wave" side are sheaves, which, loosely speaking, are rules assigning vector spaces to points on a surface. Gaitsgory has dedicated much of the last 30 years to the geometric Langlands conjecture. In 2013 he wrote an outline of the steps required for a proof, and after more than a decade of intensive research in 2024 he and his colleagues published the full proof, comprising over 800 pages spread over 5 papers. This is a monumental advance, expected to have deep implications in other areas of mathematics too, including number theory, algebraic geometry and mathematical physics. Special Breakthrough Prize in Fundamental Physics Gerard 't Hooft, winner of the Special Breakthrough Prize in Fundamental Physics, is one of the world's most pre-eminent theoretical physicists. In the early 1970s he made crucial contributions to the foundations of what would later become known as the Standard Model of the subatomic particles. He proved that Yang-Mills theories (the mathematical framework underlying theories of both the weak and strong nuclear forces) make sense when treated quantum mechanically – that they can give finite, calculable results rather than meaningless infinities – thus validating theories which became central to the Standard Model. He made several crucial contributions to understanding the theory of the strong force, including resolving a major problem involving the masses of particles through special field configurations called instantons; he developed new mathematical tools for studying strongly interacting quarks; and he introduced the fruitful approach of studying the strong force by imagining it is mediated by many more varieties of quarks and gluons than it actually is. These and other contributions helped establish the Standard Model as a workable theory and provided powerful tools for calculating its predictions. 't Hooft has studied the quantum effects that can explain how information is processed in black holes, which led to the development of the holographic principle in cosmology, and possibly to new alternative ways to interpret quantum mechanics. New Horizons in Physics Prize This year's New Horizons in Physics Prizes honor early-career researchers across a wide range of fields. In atomic physics, Waseem Bakr has created quantum gas microscopes that can image individual atoms confined in an optical lattice, advancing the study of strongly interacting quantum systems. In quantum information, a field at the fertile intersection of physics, mathematics and computer science, Jeongwan Haah has developed models of emergent quantum systems –macroscopic systems exhibiting quantum behavior, whose potential applications include quantum computing; these models include 'Haah's code', which has opened the field of a class of quasi-particles called fractons. And in astronomy, Sebastiaan Haffert, Rebecca Jensen-Clem and Maaike van Kooten have designed and enabled novel techniques for extreme adaptive optics, which are systems that compensate for the effects of Earth's atmosphere on light reaching terrestrial telescopes. Their work promises to enable the direct detection of the smallest exoplanets. New Horizons in Mathematics Prize Modern physics and higher mathematics share intimate connections, and it is notable that the research areas of all three of this year's New Horizons in Mathematics Prize winners have links to quantum physics. Ewain Gwynne is recognized for his work in conformal probability, which studies probabilistic objects such as random curves and surfaces. John Pardon has produced a number of important results in geometry and topology, particularly in the field of symplectic geometry and pseudo-holomorphic curves, which are certain types of smooth surfaces in manifolds. Sam Raskin has played a significant role in the major recent progress on the geometric Langlands program (see Mathematics section above), including the final proof of the geometric Langlands conjecture in characteristic 0. Maryam Mirzakhani New Frontiers Prize The Maryam Mirzakhani New Frontiers Prize is awarded to outstanding women mathematicians who have recently completed their PhDs. Si Ying Lee has found a new approach to an important problem in the Langlands program (see Mathematics section above), succeeding in reducing it to a local problem. Rajula Srivastava has made progress in a challenging area at the intersection of harmonic analysis and number theory. Her work focuses on bounding the number of lattice points one can find near a given smooth surface, with important applications to Diophantine approximation in higher dimensions. Ewin Tang has invented quantum computing algorithms for machine learning. She also proved that certain calculations, which quantum algorithms were widely considered to be exponentially faster at solving, can actually be solved in comparable time by a normal (non-quantum) computer. Citations for 2025 Laureates 2025 Breakthrough Prize in Life Sciences Daniel J. Drucker Lunenfeld-Tanenbaum Research Institute, Sinai Health, and University of Toronto Joel Habener Massachusetts General Hospital and Harvard University Jens Juul Holst Novo Nordisk Foundation Center for Basic Metabolic Research and the Department of Biomedical Sciences, University of Copenhagen Lotte Bjerre Knudsen Novo Nordisk Svetlana Mojsov Rockefeller University For the discovery and characterization of GLP-1 and revealing its physiology and potential in treating diabetes and obesity. 2025 Breakthrough Prize in Life Sciences Alberto Ascherio Harvard University Stephen L. Hauser University of California, San Francisco For establishing the role of B cells in multiple sclerosis and developing B-cell based treatments, and for revealing that Epstein-Barr virus infection is the leading risk for multiple sclerosis. 2025 Breakthrough Prize in Life Sciences David R. Liu Merkin Institute for Transformative Technologies in Healthcare at the Broad Institute of MIT and Harvard, Harvard University, and Howard Hughes Medical Institute For developing base editing and prime editing, technologies that edit the DNA of living systems without cutting the DNA double helix, and rewrite segments of genes at their native locations, enabling the correction or replacement of virtually any mutation. 2025 Breakthrough Prize in Fundamental Physics The ATLAS, CMS, ALICE and LHCb Collaborations at CERN's Large Hadron Collider For detailed measurements of Higgs boson properties confirming the symmetry-breaking mechanism of mass generation, the discovery of new strongly interacting particles, the study of rare processes and matter-antimatter asymmetry, and the exploration of nature at the shortest distances and most extreme conditions at CERN's Large Hadron Collider. The $3 million prize is allocated to ATLAS ($1 million); CMS ($1 million), ALICE ($500,000) and LHCb ($500,000), in recognition of 13,508 co-authors of publications based on LHC Run-2 data released between 2015 and July 15, 2024. [ATLAS – 5,345 researchers; CMS – 4,550; ALICE – 1,869; LHCb – 1,744]. In consultation with the leaders of the experiments, the Breakthrough Prize Foundation will donate 100 percent of the prize funds to the CERN & Society Foundation. The prize money will be used by the collaborations to offer grants for doctoral students from member institutes to spend research time at CERN, giving the students experience working at the forefront of science and new expertise to bring back to their home countries and regions. The names of each prizewinner can be found at . 2025 Special Breakthrough Prize in Fundamental Physics Gerardus 't Hooft Utrecht University For fundamental insights into gauge theory and the standard model. 2025 Breakthrough Prize in Mathematics Dennis Gaitsgory Max Planck Institute for Mathematics For foundational works and numerous breakthrough contributions to the geometric Langlands program and its quantum version; in particular, the development of the derived algebraic geometry approach and the proof of the geometric Langlands conjecture in characteristic 0. 2025 New Horizons in Mathematics Prize Ewain Gwynne University of Chicago For contributions to conformal probability, in particular to the understanding of the LQG metric. John Pardon Stony Brook University For contributions to symplectic topology and other areas of geometry and topology. Sam Raskin Yale University For contributions to the geometric Langlands program, including the theory of the Whittaker model and the proof of the geometric Langlands conjecture in characteristic 0. 2025 Maryam Mirzakhani New Frontiers Prize Si Ying Lee Stanford University (PhD Harvard University 2022) For contributions to the theory of Shimura varieties. Rajula Srivastava University of Bonn and Max Planck Institute for Mathematics (PhD University of Wisconsin 2022) For contributions in harmonic analysis and analytic number theory, including contributions to the problem of counting rational points near smooth manifolds. Ewin Tang University of California, Berkeley (PhD University of Washington 2023) For developing classical analogs of quantum algorithms for machine learning and linear algebra, and for advances in quantum machine learning on quantum data. 2025 New Horizons in Physics Prize Waseem Bakr Princeton University For the realization of quantum gas microscopes for atoms and molecules, providing a microscopic view on correlations and transport in strongly interacting quantum systems. 2025 New Horizons in Physics Prize Jeongwan Haah Stanford University For the discovery of Haah's code, in which fractal conservation laws emerge, and other models bringing discrete mathematical structures to physics 2025 New Horizons in Physics Prize Sebastiaan Haffert Leiden University, Leiden Observatory and University of Arizona, Steward Observatory Rebecca Jensen-Clem University of California, Santa Cruz Maaike van Kooten National Research Council Canada For demonstrating new extreme adaptive optics techniques that will allow the direct detection of the smallest exoplanets. About The Breakthrough Prize For the 13th year, the Breakthrough Prize, renowned as the "Oscars ® of Science," recognizes the world's top scientists. Each prize is $3 million and presented in the fields of Life Sciences, Fundamental Physics and Mathematics. In addition, up to three New Horizons in Physics Prizes, up to three New Horizons in Mathematics Prizes and up to three Maryam Mirzakhani New Frontiers Prizes are given out to early-career researchers each year. Laureates attend a gala award ceremony designed to celebrate their achievements and inspire the next generation of scientists. The Breakthrough Prizes were founded by Sergey Brin, Priscilla Chan and Mark Zuckerberg, Julia and Yuri Milner, and Anne Wojcicki and have been sponsored by foundations established by them. Selection Committees composed of previous Breakthrough Prize laureates in each field choose the winners. Information on the Breakthrough Prize is available at . SOURCE The Breakthrough Prize WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Collins first joined the NIH in 1993 to lead the Human Genome Project.\n After a 32-year career at the National Institutes of Health, Francis Collins, M.D., Ph.D., retired from the agency, effective Feb. 28.The NIH “has been rightfully called the ‘crown jewel’ of the federal government for decades,” Collins said in a March 1 statement (PDF). “It has been the greatest honor of my life to be part of this institution in various roles over the last four decades.”Collins served as NIH director from 2009 to 2021, spanning three presidents: Barack Obama, Donald Trump and Joe Biden. After stepping down as director, he briefly served as Biden’s science advisor in 2022. He then returned to the NIH’s National Human Genome Research Institute, where he had served as director from 1993 to 2008. There, Francis led the Human Genome Project, which successfully finished compiling a full human genome in 2003. Throughout his NIH career, Collins’ research group focused on type 2 diabetes and a rare disease called progeria, which causes premature aging. His group’s work helped lead to the first approved therapy for the disease, Sentynl Therapeutics’ Zokinvy (lonafarnib). Sentynl acquired the rights to Zokinvy from original developer Eiger BioPharmaceuticals in 2024.In his statement, Collins hailed the NIH as the “main piston of a biomedical discovery engine that is the envy of the globe,” adding that the agency’s employees “deserve the utmost respect and support of all Americans.”Collins is the latest federal health agency leader to depart since President Donald Trump was reelected and inaugurated for a second term. For example, the NIH’s Deputy Director for Extramural Research Michael Lauer, M.D., left the agency a few weeks ago, while Principal Deputy Director Larry Tabak, Ph.D., retired.Under the new administration, scores of federal employees have been fired, research grants have been canceled and the Elon Musk-led Department of Government Efficiency has terminated leases for 30 FDA facilities across 23 states. 

MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the "Company", an emerging leader in age-reversal science, today announced significant findings from its copper binding studies with Telomir-1. This is a promising development as the company explores Telomir-1 for the treatment of Wilson's disease and other copper related disorders. The announcement marks an important step forward in Telomir's mission to address critical unmet medical needs while continuing to explore transformative therapies.Key FindingsRecent preclinical in vitro studies conducted by Recipharm and Smart Assays have demonstrated Telomir-1's exceptional binding affinity for copper ions, highlighting its ability to selectively interact with and regulate copper metabolism. Additionally, Telomir-1's capability to bind and exchange key ions, including copper, iron, and zinc, emphasizes its unique profile and positions it as a promising candidate for further research. These findings form a strong foundation for investigating Telomir-1's potential in addressing Wilson's disease, a rare genetic disorder characterized by excessive copper accumulation that can result in significant damage to the liver, brain, and other vital organs.Wilson's Disease: A Critical Unmet NeedWilson's disease is a rare genetic disorder that affects approximately 1 in 30,000 individuals worldwide. The condition is caused by mutations in the ATP7B gene, which impair the body's ability to properly regulate copper metabolism. As a result, copper accumulates to toxic levels, particularly in the liver and brain, leading to severe and potentially life-threatening complications, including liver failure, neurological damage, and psychiatric disorders. Left untreated, Wilson's disease is fatal.Current treatments for Wilson's disease, such as chelating agents (e.g., penicillamine and trientine) and zinc therapy, are primarily aimed at reducing copper levels in the body. While these treatments can be effective, they come with significant drawbacks, including:Chelating agents often cause severe side effects, including kidney damage, bone marrow suppression, and gastrointestinal issues. Additionally, these drugs require lifelong adherence, which can be burdensome for patients.Zinc therapy works by preventing copper absorption in the gut but can result in side effects like anemia, gastrointestinal discomfort, and reduced effectiveness over time.The limitations of current therapies underscore the urgent need for new treatment options that address the root cause of Wilson's disease while minimizing side effects. Telomir-1's copper binding properties hold the potential to offer a safer, more effective alternative that directly targets the underlying mechanisms of the disease. The designation of Wilson's disease as a rare and life-threatening condition also positions it as a candidate for orphan drug designation, which could accelerate development timelines and provide additional regulatory and financial incentives."These recent groundbreaking results on copper binding and interaction showcase Telomir-1's potential to address a significant unmet need in Wilson's disease by enabling beneficial regulations at the underlying causes rather than just managing the symptoms of the disease," said Dr. Itzchak Angel, Chief Scientific Advisor at Telomir. "This is a pivotal moment as we work to bring transformative therapies to patients who need them most."Update on Previous Osteoarthritis StudyEarlier this year, Telomir partnered with Midwest Veterinary Services to launch a planned large-scale study on osteoarthritis in dogs. While only the safety phase of the study was completed-showing no adverse effects-the Company chose to discontinue the study. This decision was based on the requirement to induce osteoarthritis in the dogs, a practice that conflicted with the new management's commitment to the Company's mission and values. Instead, the Company is now in discussions with a well-known veterinary institution to design a new study that will recruit elderly dogs who naturally suffer from osteoarthritis. As such, Telomir is committed to obtaining an INAD (Investigational New Animal Drug) application for pets while progressing toward an IND (Investigational New Drug) application for humans.Expanding Research and DevelopmentBuilding on these results, Telomir is planning and advancing studies to expand the therapeutic potential of Telomir-1. Key ongoing initiatives include:Wilson's Disease Study: Investigating Telomir-1's effects on copper regulation in preclinical models.Type 2 Diabetes Studies: After the success achieved with the zebrafish model, Telomir is currently conducting a rat diabetic model to further strengthen the data on Telomir-1's efficacy in reversing key metabolic parameters.Progeria Research: Examining Telomir-1's impact on accelerated aging and telomere function.Cancer Models: Exploring anti-cancer applications using xenograft studies.Alzheimer's Disease: Investigating Telomir-1 for its potential to mitigate cognitive decline and neurodegeneration associated with Alzheimer's.Metal Toxicity: Exploring Telomir-1's role in addressing metal toxicity, which occurs when metals like copper, iron, or lead accumulate to harmful levels in the body. Metal toxicity can disrupt cellular function, lead to oxidative stress, and contribute to chronic and age-related diseases. By regulating metal levels, Telomir-1 aims to restore cellular balance and reduce associated health risks.DNA Methylation Analysis: Investigating Telomir-1's role in modulating DNA methylation rates, which influence gene expression and play a key role in aging and disease progression.DNA methylation, the addition of chemical groups to DNA, can disrupt normal gene function when dysregulated, contributing to various chronic and age-related diseases. By addressing these epigenetic changes, Telomir-1 aims to restore healthy gene expression patterns.Clinical Progress and Future MilestonesBuilding on our preclinical success demonstrating the potential for age reversal, improved longevity, and health span, as well as the reversal of key Type 2 diabetes parameters, the Company is committed to unlocking the full potential of Telomir-1 to revolutionize the treatment of age-related diseases by addressing their root causes. The possibilities are vast, and we believe this drug holds extraordinary promise to potentially transform the pharmaceutical industry.As we continue to gather scientific data and delve deeper into the molecular mechanisms of action of Telomir-1, we are positioning ourselves to identify the most impactful indication for our initial IND application. The Company is currently working on the optimization of manufacturing processes to enable an affordable and scalable approach. This will support the production of GMP-grade quantities necessary for IND-enabling studies and clinical trials. The Company plans to carry out the IND-enabling safety studies in Q2 2025, targeting IND submission by Q4 2025, with first-in-human clinical trials anticipated in the first half of 2026. The company also plans to secure an INAD for pets, paving the way for Telomir-1's dual application in both human and veterinary medicine.Market PotentialThe global anti-aging drugs market is experiencing significant growth, driven by increasing demand for treatments that address age-related diseases and promote longevity. In 2024, the market was valued at approximately USD 91.05 billion and is projected to reach USD 160.24 billion by 2031, growing at a compound annual growth rate (CAGR) of 7.32% during this period. This expansion reflects a rising consumer focus on health and wellness, advancements in medical research, and a growing aging population seeking solutions to enhance quality of life. (Verified Market Research)Telomir-1 represents a novel approach by targeting the root causes of age-related diseases rather than simply managing symptoms. By developing therapies that extend health span and enhance quality of life, the Company seeks to redefine patient care and make a meaningful impact in this rapidly growing multi-billion-dollar market.Leadership Perspective"As we look to 2025, Telomir remains dedicated to its mission," said Erez Aminov, Chairman and CEO of the Company. "We are pleased to have secured additional financing at a 20% premium with no warrants, providing the resources needed to continue advancing Telomir-1's development while focusing on creating value for our shareholders."About Telomir Pharmaceuticals, Inc.Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) is a pre-clinical stage pharmaceutical company seeking to lead development in several areas, including age-reversal science. Telomir is focused on the development of Telomir-1, a novel small molecule designed to lengthen the DNA's protective telomere caps, which are crucial in the aging process. Telomir's goal is to explore the potential of Telomir-1 starting with ongoing research in animals and then in humans.Telomeres are the protective end caps of a chromosome made up of DNA sequences and proteins. As humans age, telomeres shorten, with metal reactivity accelerating the process, which presents humans and pet animals with an increased chance of contracting a number of degenerative and age-related diseases. Telomir's goal is to develop and gain regulatory approval for Telomir-1, proposed to be dosed orally, with the broader aim of promoting longevity and enhancing overall quality of life.The Nobel Assembly at Karolinska Institute (Sweden) awarded the Nobel Prize in Physiology or Medicine in 2009 for the discovery of how chromosomes are protected by telomeres and the enzyme telomerase.Telomir-1 is in preclinical development and has not yet been tested in humans. There is no assurance that Telomir-1 will proceed through development or will ultimately receive FDA approval for marketing.Cautionary Note Regarding Forward-Looking StatementsThis press release, statements of Telomir Pharmaceuticals' management or advisors related thereto, and the statements contained in the news story linked in this release contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding (i) the anticipated benefits of the preclinical testing results described herein, (ii) anticipated timelines and subject matter for additional preclinical and clinical testing of Telomir-1 and (iii) the potential therapeutic benefits of Telomir-1 generally.Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release and are subject to a number of significant risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications and safety of Telomir-1. These and other risks concerning Telomir's programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which is on file with the SEC. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.Telomir's lead compound, Telomir-1, is being investigated for its potential to address a range of conditions, including Type 2 diabetes, Wilson's disease, progeria, Alzheimer's disease, and cancer. The company's innovative approach aims to treat the root causes of disease, offering a promising path forward in improving patient care.For more information, visit www.telomirpharma.com.Contact InformationHelga Moya [email protected](786) 396-6723SOURCE: Telomir Pharmaceuticals, Inc.